We therefore propose that, while activators of AMPK may prove to be useful in prevention of cancer, most likely in individuals who have a high genetic risk of developing the disease, inhibitors of AMPK may instead be efficacious in the treatment of pre-existing cancers. The gene discussed is PRKAB1; the disease is cancer.